For Previously Treated Metastatic Gastric Cancer, Pemetrexed Alone May Be Safe, Effective
the Cancer Therapy Advisor take:
According to a new study published in the British Journal of Cancer, monotherapy with pemetrexed shows activity and is well tolerated for the treatment of previously treated patients with metastatic gastric cancer.
Because of the wide debate surrounding second-line and beyond chemotherapy for the treatment of metastatic gastric cancer, researchers sought to investigate the efficacy and safety of pemetrexed alone in previously treated patients with metastatic stomach cancer.
For the single-arm, phase 2 study, researchers enrolled 34 patients into the study. All patients received pemetrexed 500mg/m2 intravenously every 21 days until disease progression or unacceptable toxicity.
At the time of analysis, 34 patients were evaluable for toxicity and 30 were evaluable for response. Results showed that 13.3% of patients achieved a partial response, 50% had stable disease, and 36.7% had progressive disease as the best response. The median progression-free survival was 2.2 months (95% CI: 2.0 - 5.5) and the median overall survival was 6.4 months (95% CI: 5.8 - 9.5). The most common severe adverse events were anorexia, fatigue, neutropenia, transaminase elevation, thrombocytopenia, and weight loss.
According to the American Cancer Society, gastric cancer is a leading cause of cancer-related deaths in the world, particularly in less developed countries.
Monotherapy with pemetrexed shows activity for the treatment of previously treated patients with metastatic gastric cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC
- Pembrolizumab Alone or With Chemotherapy Prolongs OS in Recurrent/Metastatic HNSCC
- Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma
- Assays May Help Researchers Discover Factors Underlying Immunotherapy Response
- Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer